Tempus AI Surges 30% in a Week on Cancer Test Launch, but Trades at -618x Earnings
NEW YORK, April 19 —
Tempus AI ripped 30% in a single week after launching a new cancer test kit and inking a genomics partnership, closing at $55.87.
- TEM shares jumped 13.9% in one session on the cancer test kit unveiling, part of a 30% weekly gain
- The stock trades at -618x forward P/E on $1.3bn trailing twelve-month revenue, meaning Wall Street expects losses to continue
- Watch next quarterly earnings for diagnostics revenue growth and any FDA milestones on the new test kit
What Actually Happened
Two catalysts stacked on top of each other. First, Tempus partnered with Predicta Biosciences to broaden access to the GenoPredicta ultrasensitive whole-genome sequencing assay. Then the company unveiled a new cancer test kit, which lit the fuse for the 13.9% single-day move. Cathie Wood's ARK Innovation ETF piled in with a $2.5mn purchase, which probably amplified the momentum. ARK buying a money-losing AI diagnostics company is not exactly contrarian at this point, but it does signal to retail that "smart money" is interested. Retail follows ARK flows like a hawk.
The Catch
A -618x forward P/E tells you something important: this company is not close to profitability. That number means analysts expect Tempus to keep burning cash even as revenue scales. The $1.3bn in trailing revenue sounds impressive until you realize the market is pricing the stock as if profitability is several years away. Partnerships and product launches generate headlines. They do not generate earnings. The genomics diagnostics space is also crowded. Guardant Health, Exact Sciences, and Natera all compete for oncology testing dollars, and each has a head start on commercialization. A 30% weekly run-up on a partnership announcement and a test kit launch, not an FDA approval or a blockbuster earnings beat, prices in a lot of good news that hasn't actually materialized yet.
Bottom Line
The GenoPredicta partnership and cancer test kit do expand Tempus's precision oncology product line. That's real. But a 30% move in five trading days on pre-revenue catalysts is the market paying tomorrow's prices today. If you're a growth investor, the next earnings report is the moment of truth: does diagnostics revenue accelerate enough to justify this valuation, or was this just a momentum trade dressed up as a fundamental story? The number to watch is diagnostic segment revenue growth, quarter over quarter.
For a full breakdown of Tempus AI's financials and valuation, generate a free Basis Report here.
Basis Report does not hold positions in securities discussed. This is not investment advice.